CVS Health vs Humana

Goldman recommends defensive stocks amid AI bull concerns

Goldman Sachs advises investors concerned about a potential slowdown in the AI trade to consider defensive stocks in health care and consumer staples. The bank notes that AI capital spending currently contributes about half of S&P 500 earnings growth, but expects this to diminish as spending growth slows. Rising energy prices and interest rates are clouding the economic outlook, with higher financing costs raising doubts about the durability of the AI infrastructure buildout. Goldman's screen highlights companies with high free cash flow yields and recent underperformance, such as Tyson Foods (11% FCF yield, down 17% over six months) and CVS Health (9% FCF yield, down 15% in three months). Despite these defensive recommendations, Goldman's base case still expects continued earnings growth, with a potential catch-up trade in consumer-facing stocks fueled by weaker energy prices and falling interest rates anticipated in 2027.

• Goldman Sachs recommends defensive stocks in health care and consumer staples amid AI trade concerns.
• AI capital spending contributes about half of S&P 500 earnings growth, but Goldman expects this to diminish.
• Rising energy prices and interest rates are clouding the economic outlook.

10-Q Financial Filing Analysis for CVS Health (2026-08-05)

CVS Health Corporation reported strong financial results for the second quarter of 2026, driven by top-line growth across all major operating segments. Total revenues increased 7.3% year-over-year to $106.10 billion, up from $98.92 billion in Q2 2025. Operating income saw a substantial 97.5% increase to $4.70 billion, compared to $2.38 billion in the prior-year period, primarily supported by core operational improvements and the absence of $833 million in legacy litigation charges incurred in Q2 2025. Net income attributable to CVS Health rose significantly to $2.98 billion ($2.31 diluted EPS) from $1.02 billion ($0.80 diluted EPS). Performance in the Health Care Benefits segment reflected improved medical loss dynamics, with the Medical Benefit Ratio (MBR) declining to 87.4% from 89.9% in Q2 2025, driven by improved underlying Government business performance and the absence of prior-year premium deficiency reserves. Growth was supported by the Health Services segment, where revenues climbed 11.5% to $51.80 billion, and Pharmacy & Consumer Wellness, which posted a 2.9% increase in pharmacy same-store sales aided by Rite Aid file acquisitions. In regulatory matters, CVS reached a proposed settlement with the FTC to resolve outstanding PBM and pharmacy inquiries.

• Q2 2026 consolidated total revenues reached $106.10 billion, an increase of 7.3% year-over-year, with operating income increasing 97.5% to $4.70 billion.
• Health Care Benefits Medical Benefit Ratio (MBR) improved by 250 bps year-over-year to 87.4%, while total medical membership stood at 26.02 million as of June 30, 2026.
• Operating cash flow for the first six months of 2026 increased 64.2% year-over-year to $10.59 billion, supporting $3.29 billion in long-term debt repayments.

Pixability Appoints Norm de Greve, Former General Motors CMO and Chairman of the MMA, to its Advisory Board

Norm de Greve, former CMO of General Motors and CVS Health and Chairman of the MMA, has joined the advisory board of Pixability, a leading AI-driven technology company that helps brands maximize YouTube advertising. In an interview with AdExchanger, de Greve highlights common mistakes brands make with YouTube marketing, emphasizing the need for an integrated strategy across paid, owned, and creator channels, which most brands lack. He also notes YouTube's growing importance as a top source for AI search and advocates for a holistic approach to content and creator management. De Greve critiques current AI use in marketing, urging brands to redesign workflows around AI rather than optimize old processes. Pixability's AI-driven approach aims to help marketers analyze organic content, amplify successful strategies, and allocate budgets more effectively across YouTube's ecosystem.

• Norm de Greve, former CMO of General Motors and CVS Health and Chairman of the MMA, joined Pixability's advisory board.
• Pixability is a YouTube-focused AI company that helps brands maximize paid and owned media and leverage creators.
• De Greve advises brands to integrate paid, owned, and creator YouTube strategies.

8-K Financial Filing Analysis for Humana (2026-10-13)

On October 13, 2026, Humana Inc. announced a new joint venture arrangement with funds managed by HPS Investment Partners, a subsidiary of BlackRock, Inc., to manage and operate its CenterWell Senior Primary Care clinic network. This arrangement replaces CenterWell's existing joint venture with Welsh, Carson, Anderson & Stowe (WCAS), with BlackRock acquiring WCAS's equity stake under modified terms. Notably, the new JV eliminates the previous put option held by WCAS, resulting in an expected significant reduction in balance sheet liabilities and a lower overall cost of capital. Concurrently, Humana reaffirmed its FY 2026 Adjusted EPS guidance of at least $9.00.

• BlackRock subsidiary HPS Investment Partners acquired WCAS's equity stake in CenterWell Senior Primary Care clinics under a restructured joint venture eliminating previous put option liabilities.
• CenterWell secures the option to purchase clinics starting in 2028, with BlackRock holding exit rights via a sale process by end-2033 if clinics remain unacquired.
• Humana reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 per common share.

8-K Financial Filing Analysis for Humana (2026-10-09)

Humana Inc. announced that it has exceeded its goal of Top Quartile results for the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028), based on final data released by the Centers for Medicare and Medicaid Services (CMS) on October 8, 2026. Top Quartile performance is defined as Stars revenue per member per month (PMPM) at least 10% above the peer group median. While anticipating that a portion of the 2028 bonus outperformance will be one-time in nature, Humana expects to utilize the resulting financial benefit for one-time investments and capital returns to shareholders. Concurrently, the company reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 and announced a virtual investor update scheduled for December 10, 2026.

• Exceeded the Top Quartile target for 2027 CMS Medicare Advantage Star Ratings (Bonus Year 2028), defined as Stars revenue PMPM 10% above the peer group median.
• Reaffirmed full-year 2026 Adjusted EPS guidance of at least $9.00 per share.
• Scheduled a virtual investor update for December 10, 2026, to review progress against the multi-year earnings framework through 2028.

Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027

Press Release | 10/01/2026 Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027